Inside fetal anaemia: intrauterine transfusion methods and outcomes

Fetal anaemia arises when red cell destruction, suppression, or loss exceeds the fetal marrow's compensatory capacity. Severe anaemia before birth can progress to high-output cardiac failure, hydrops, and stillbirth, particularly when the haemoglobin deficit exceeds 2 g/dL below the gestational mean. Intrauterine transfusion (IUT) has served as the principal rescue therapy since the 1960s, and ultrasound-guided delivery of packed red cells into the fetal circulation now sustains many pregnancies that would otherwise end in perinatal loss.

The scientific programme of the perinatal congress and the resources on the FAOPS 2020 platform reflect the multidisciplinary nature of this work, with obstetricians, haematologists, and neonatologists collaborating across the Asia–Oceania region. In Australia, a small number of metropolitan fetal medicine units shoulder most of this workload, supported by Medicare funding, strict laboratory governance, and referral pathways that span thousands of kilometres between capital cities and remote communities.

Aetiology and pathophysiology of fetal anaemia

Alloimmunization remains the leading indication, most often involving the Rh-D antigen but also Kell, c, E, and less common targets. Maternal IgG crosses the placenta and opsonises fetal red cells, with haemolysis accelerating as the spleen and liver become overwhelmed. Parvovirus B19 acts differently, halting erythroid precursor production in the marrow for one to three weeks after maternal viraemia and causing transient aplastic anaemia.

Fetomaternal haemorrhage, twin-to-twin transfusion, and rare genetic disorders account for smaller case numbers. The fetal response to falling oxygen delivery includes increased cardiac output, cerebral vasodilation, and eventual hydrops once compensatory mechanisms fail. Hydrops at presentation strongly predicts procedural difficulty and lower survival, making early detection before decompensation the central goal of surveillance.

Diagnostic evaluation before intrauterine transfusion

Assessment starts with a focused history covering prior pregnancies, transfusion events, recent infections, abdominal trauma, and maternal antibody status. Antibody identification by column agglutination or solid-phase methods pinpoints the offending antigen, while titre or quantitation guides the urgency of fetal monitoring. Middle cerebral artery peak systolic velocity (MCA-PSV) measured during fetal quiescence provides a sensitive non-invasive surrogate for severity, with values above 1.5 multiples of the median prompting formal evaluation.

Cordocentesis confirms the haemoglobin, haematocrit, reticulocyte count, and direct antiglobulin status, and is performed at the same sitting as the therapeutic transfusion when intervention is required. In Australia, compatible donor units come from Australian Red Cross Lifeblood, typically O-negative, cytomegalovirus-negative, washed or volume-reduced, and irradiated to prevent graft-versus-host disease. Turnaround for highly matched units can extend over several days, particularly in regional laboratories, influencing the timing of planned procedures.

Techniques for delivering intrauterine blood transfusion

Intravascular transfusion via the umbilical vein is the standard technique. Access is generally obtained at the placental cord insertion, a free loop of cord, or the intrahepatic vein, with selection based on placental position, fetal lie, and operator experience. A 20- or 22-gauge needle is introduced under continuous ultrasound, a short-acting neuromuscular blocker such as vecuronium may be given to the fetus when movement is problematic, and donor blood is infused by calibrated syringe pump while heart rate and needle position are observed throughout.

Volume is calculated to reach a target post-procedure haematocrit of 40 to 45 percent in the non-hydropic fetus, adjusting for donor unit haematocrit and fetoplacental blood volume. Procedures usually take 10 to 30 minutes and conclude with sampling to document final haemoglobin and biochemical state. Intraperitoneal transfusion has largely fallen from routine practice because intravascular access is feasible from around 16 weeks onward, although it retains a niche role in extreme early gestation or when vascular access fails and the diaphragm remains competent.

Procedural risks and immediate complications

Procedural loss rates in experienced hands are typically one to three percent per transfusion, with higher risk in hydropic fetuses, early gestation, and difficult access. Acute complications include umbilical cord spasm, fetal bradycardia, needle displacement, and puncture-site haemorrhage. Post-procedurally, teams watch for rebound cardiac decompensation as circulating volume redistributes, with emergency delivery capacity immediately available.

Cord blood sampling at the conclusion of the procedure documents the post-transfusion haematocrit and provides biochemical feedback. Acid-base status, lactate, and glucose correlate with the duration and complexity of the transfusion. Detailed interpretation of cord blood gas values in the perinatal setting is examined in the article the-use-of-cord-blood-gas-analysis-in-delivery-room-management, which complements intraprocedural monitoring with delivery-room relevance for infants born soon after transfusion.

Core procedural safeguards during IUT include:

• Continuous ultrasound guidance with clear visualisation of the needle tip at all times
• Donor units that are O-negative, CMV-negative, irradiated, and cross-matched against the maternal serum
• Real-time fetal heart rate monitoring throughout the infusion
• Paediatric and anaesthetic teams immediately available for emergency delivery

Long-term outcomes among survivors

Survivors face risks that extend well beyond the neonatal period. The underlying aetiology shapes neurodevelopment: alloimmune cases treated before hydrops generally show outcomes comparable to unaffected peers, while viral-induced anaemia and severe early-onset hydrops carry higher rates of sensorineural hearing loss, cerebral palsy, and cognitive delay. Structured follow-up through school age with audiology, psychology, and developmental paediatrics is recommended for all IUT survivors.

Postnatal care also involves suppression of ongoing maternal antibody production in alloimmune disease, exchange transfusion when persistent haemolysis is severe, and iron-chelation planning if an underlying transfusion-dependent thalassaemia emerges. Coordination between fetal medicine and neonatal intensive care teams at the delivering hospital smooths the transition from intrauterine support to extrauterine management, particularly when delivery follows shortly after the final transfusion.

Predictors of a favourable long-term outcome include:

• Absence of hydrops at first transfusion
• Underlying alloimmunization rather than viral aplasia or massive fetomaternal haemorrhage
• Delivery at term or near term without severe metabolic acidosis
• Multidisciplinary neurodevelopmental surveillance through childhood

Service delivery across Australian tertiary centres

Australian practice operates through a handful of high-volume fetal medicine units in Sydney, Melbourne, Brisbane, Adelaide, and Perth, each serving catchments that span multiple states. Patients from Cairns, Townsville, Darwin, and Kalgoorlie often relocate for serial procedures, with telehealth consultations supporting remote counselling and post-procedure review. Medicare rebates cover the procedural component under specialist obstetric codes, and private health insurers contribute when care occurs in private maternity hospitals.

The National Blood Authority and Australian Health Ministers' Advisory Council set standards for laboratory practice and traceability of donor products, while the Therapeutic Goods Administration regulates diagnostic devices and blood component manufacture. State-based legislation such as Queensland's Termination of Pregnancy Act 2018 shapes counselling pathways when severe early disease is identified, requiring clinicians to navigate these considerations sensitively. Training through the Royal Australian and New Zealand College of Obstetricians and Gynaecologists and the Society of Obstetric Medicine of Australia and New Zealand sustains a small but experienced workforce, and adjunctive postnatal practices highlighted at recent meetings are discussed in the piece on the-importance-of-kangaroo-mother-care-during-infectious-outbreaks.

Emerging research and adjunctive strategies

Several questions remain active. Non-invasive fetal genotyping using cell-free DNA from maternal plasma has reduced unnecessary invasive testing in alloimmunised pregnancies, particularly for Kell and other less common antigens, and continues to expand. Refinements to MCA-PSV thresholds adjusted for gestational age and the interval since prior transfusion are being evaluated in international cohorts. Maternal immunoglobulin infusion and other immunomodulatory strategies have shown limited benefit and remain investigational.

Future directions focus on reducing procedural volume through earlier detection, optimising donor unit quality to extend inter-transfusion intervals, and integrating image-guided tools that improve needle trajectory. Collaborative networks documented through bodies such as the JCR 2020 community bring together multidisciplinary groups interested in placental insufficiency and fetal therapy. The exchange of protocols between Australian centres and their Asia–Oceania neighbours through the FAOPS platform continues to shape practice, particularly for rare antigens and complex referrals.

The perinatal community remains committed to refining intrauterine transfusion so that fewer pregnancies end in loss and more children grow up without neurological consequence. Specialists, trainees, and researchers can deepen their understanding by exploring the full scientific programme, accessing related educational content, and registering interest through the official congress channels. Collaboration across disciplines and borders will determine how quickly diagnostic precision, procedural safety, and long-term outcomes continue to improve for families facing this challenging diagnosis.